Johnson & Johnson (NYSE:JNJ) Shares Purchased by Walkner Condon Financial Advisors LLC

Walkner Condon Financial Advisors LLC boosted its stake in Johnson & Johnson (NYSE:JNJ) by 32.6% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 2,601 shares of the company’s stock after purchasing an additional 639 shares during the period. Walkner Condon Financial Advisors LLC’s holdings in Johnson & Johnson were worth $408,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Moneta Group Investment Advisors LLC boosted its position in Johnson & Johnson by 90,144.4% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 54,386,720 shares of the company’s stock valued at $9,607,414,000 after buying an additional 54,326,454 shares during the period. Morgan Stanley boosted its position in Johnson & Johnson by 12.0% in the 4th quarter. Morgan Stanley now owns 42,224,521 shares of the company’s stock valued at $7,458,962,000 after buying an additional 4,521,062 shares during the period. Norges Bank purchased a new position in Johnson & Johnson in the 4th quarter valued at approximately $4,609,399,000. Charles Schwab Investment Management Inc. boosted its position in Johnson & Johnson by 1.9% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 17,189,229 shares of the company’s stock valued at $3,046,449,000 after buying an additional 328,297 shares during the period. Finally, Barclays PLC boosted its position in Johnson & Johnson by 61.0% in the 2nd quarter. Barclays PLC now owns 11,287,765 shares of the company’s stock valued at $1,868,351,000 after buying an additional 4,278,512 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.

Wall Street Analyst Weigh In

JNJ has been the subject of several recent analyst reports. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, February 6th. Wells Fargo & Company cut shares of Johnson & Johnson from an “overweight” rating to an “equal weight” rating and decreased their price objective for the stock from $170.00 to $163.00 in a research report on Wednesday, December 13th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, March 13th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $181.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, February 28th. Finally, Raymond James lifted their price objective on shares of Johnson & Johnson from $172.00 to $175.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 3rd. Seven equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $177.31.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, major shareholder & Johnson Johnson sold 3,725 shares of Johnson & Johnson stock in a transaction on Friday, February 16th. The shares were sold at an average price of $25.81, for a total value of $96,142.25. Following the transaction, the insider now directly owns 4,099,575 shares in the company, valued at $105,810,030.75. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, major shareholder & Johnson Johnson sold 3,725 shares of the business’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $25.81, for a total transaction of $96,142.25. Following the transaction, the insider now directly owns 4,099,575 shares in the company, valued at $105,810,030.75. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Jennifer L. Taubert sold 59,397 shares of the business’s stock in a transaction dated Friday, February 9th. The stock was sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the transaction, the executive vice president now owns 141,416 shares in the company, valued at $22,099,078.32. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by company insiders.

Johnson & Johnson Trading Down 0.5 %

NYSE JNJ opened at $151.66 on Tuesday. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.91 and a current ratio of 1.16. The firm has a market cap of $365.47 billion, a PE ratio of 10.98, a P/E/G ratio of 2.56 and a beta of 0.53. Johnson & Johnson has a one year low of $144.95 and a one year high of $175.97. The firm’s fifty day moving average is $157.92 and its two-hundred day moving average is $156.23.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, January 23rd. The company reported $2.29 EPS for the quarter, beating analysts’ consensus estimates of $2.28 by $0.01. The company had revenue of $21.40 billion for the quarter, compared to analyst estimates of $21.02 billion. Johnson & Johnson had a net margin of 37.79% and a return on equity of 37.27%. Johnson & Johnson’s quarterly revenue was down 9.7% on a year-over-year basis. During the same period in the previous year, the business posted $2.35 earnings per share. Analysts expect that Johnson & Johnson will post 10.65 earnings per share for the current year.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.